Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1649 1675
This examiner grants 59% of resolved cases
Brittney Erin Donoghue examines cases in Tech Center 1600 and Art Unit 1646. She has 102 resolved cases, providing a solid statistical base. The allowance rate is 58.8%. This 58.8% rate suggests that more than half of the 102 cases result in a patent grant. Practitioners should use this 58.8% figure to estimate the probability of success.
The median days to allowance is 1310. This 1310-day timeline shows that prosecution in Art Unit 1646 can be a lengthy process. A median of 1310 days is a significant duration that practitioners should factor into their long-term planning. The 1310-day figure reflects the time needed to navigate the requirements of Tech Center 1600 under this examiner.
The interview lift is 46.5%, which is a very significant figure. A 46.5% lift indicates that conducting an interview dramatically increases the likelihood of an allowance. When compared to the 58.8% base allowance rate, the 46.5% lift makes a clear case for early examiner interviews. Practitioners should use this lift as a primary tactic to overcome rejections and shorten the 1310-day path to allowance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18222093 | Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies | Non-Final OA | Janssen Biotech, Inc. |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18274677 | Astrocyte Interleukin-3 Reprograms Microglia and Limits Alzheimer`s Disease | Non-Final OA | The General Hospital Corporation |
| 18158767 | METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP | Final Rejection | SUN PHARMACEUTICAL INDUSTRIES LIMITED |
| 17600600 | COMBINATIONS OF TRANSCRIPTION INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF DISEASE | Non-Final OA | Board of Regents, The University of Texas System |
| 17798686 | ANTI-CD137 ANTIGEN-BINDING MOLECULE FOR USE IN CANCER TREATMENT | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17043537 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | Final Rejection | TORAY INDUSTRIES, INC. |
| 17785427 | BIFUNCTIONAL MOLECULES COMPRISING AN IL-7 VARIANT | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18670375 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Final Rejection | Hoffmann-La Roche Inc. |
| 17778361 | NOVEL MULTISPECIFIC ANTIBODY FORMAT | Final Rejection | AMGEN INC. |
| 17366648 | NSP-INTERLEUKIN-10 PROTEINS AND USES THEREOF | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18548477 | ANTI-CD38 ANTIBODIES FOR USE IN THE TREATMENT OF ANTIBODY-MEDIATED TRANSPLANT REJECTION | Non-Final OA | MORPHOSYS AG |
| 18314240 | OSTEOANABOLISM BY 14-3-3ZETA | Final Rejection | The University of Toledo |
| 17265731 | Enhanced Delivery of Drugs and Other Compounds to the Brain and Other Tissues | Non-Final OA | Duke University |
| 17779704 | CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS | Final Rejection | YEDA RESEARCH AND DEVELOPMENT CO. LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy